1. The NIH COVID-19 Treatment Guidelines Panel recommends use of dexamethasone 6 mg/d for up to 10 days in patients with COVID-19 who
A. Are mechanically ventilated
B. Require oxygen but are not mechanically ventilated
C. Both a and b are correct
D. Neither a, b, nor c is correct
2. In late August, FDA expanded its emergency use authorization for remdesivir to include
A. All hospitalized adult and pediatric patients with suspected or laboratory-confirmed COVID-19, regardless of disease severity
B. Hospitalized patients with COVID-19 who require supplemental oxygen but who are not on high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation
C. Hospitalized patients with COVID-19 who require supplemental oxygen and who are on high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation
D. Patients with mild or moderate COVID-19
3. In a recently published COVID-19 clinical trial conducted at 105 hospitals, which of the following adverse effects of remdesivir were more common among patients on the drug than those receiving standard care?
A. Hyponatremia, nausea, and hypokalemia
B. Nausea, hypokalemia, and headache
C. Headache, hyponatremia, and diarrhea
D. Diarrhea, hyponatremia, and nausea
4. According to a living systematic review and network meta-analysis of studies with at least 100 participants with COVID-19, lopinavir–ritonavir produced a significant difference in which of the following outcomes compared with standard care?
A. Mortality rate
B. Duration of hospital stay
C. Time to viral clearance
D. Time to symptom resolution
5. According to FDA, clinical benefits of COVID-19 convalescent plasma are most likely
A. In ambulatory patients early in the disease course, before intubation
B. In hospitalized patients early in the disease course, before intubation
C. Late in the disease course in patients on oxygen but not intubated
D. Late in the disease course in patients on oxygen who are intubated
Evaluation Questions
6. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
7. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
8. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
9. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
10. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
11. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. Will the information presented cause you to change your practice?
A. Yes
B. No
15. Are you committed to making these changes?
A. Yes
B. No
16. As a result of this activity, did you learn something new?
A. Yes
B. No
17. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
18. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20